E. Grigoryeva

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Célèste Lebbé, Nicolás Meyer, Laurent Mortier et al. · Journal of Clinical Oncology · 2019 · 398 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Georgina V. Long, Scott S. Tykodi, Jeffrey Schneider et al. · Annals of Oncology · 2018 · 202 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Paul Nathan, Paolo A. Ascierto, John B.A.G. Haanen et al. · European Journal of Cancer · 2019 · 102 citations · Full text

Medicine, Immunology, Oncology +15

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

Dirk Schadendorf, Paolo A. Ascierto, John B.A.G. Haanen et al. · European Journal of Cancer · 2019 · 44 citations

Pharmacy, Oncology, Pharmacotherapy +14

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

Dirk Schadendorf, Paolo A. Ascierto, John B.A.G. Haanen et al. · Journal of Clinical Oncology · 2017 · 25 citations

Medicine, Oncology, Pharmacology +17